The Readout

By  Damian Garde and Meghana Keshavan

A guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

A reprieve on drug ads & Gilead’s supreme clientele

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A novel approach to (disclosing) drug pricing, & a sluggish biotech IPO

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Merck’s oncologic insurgency & the FDA’s about-face on Alkermes

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

An IDO takeback & an AACR showdown

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A stock-boosting error & who’s going to win AACR?

By Damian Garde and Meghana Keshavan

The Readout

Breakthroughs that aren’t, CRISPR at the movies, & a pack of ‘Therabros’

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Sage’s scheduling intrigue & Theranos’s thinning ranks

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

David Hung’s LinkedIn selectivity & Chinese biotech looks inward

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A pharmaceutical winery & eliminating genetic middlemen

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Companies flouting disclosure laws & a look at Shire’s brutal run of form

By Damian Garde and Meghana Keshavan

Pharmalot

Pharmalittle: AstraZeneca made ‘secret’ payments to doctors; Ohio removes gags from pharmacists

By Ed Silverman

The READOUT
The Readout

CAR-T’s crowded landscape & pharma’s bad rep with patients

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Pfizer’s CAR-T move & Intra-Cellular’s long odds

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

The lessons of Alkermes & skepticism for digital health

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Behold the biotech scorecard & a CRISPR retraction

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

We can’t stop podcasting & cytokines are back

By Adam Feuerstein

The READOUT
The Readout

Amazon disrupted & an accelerated pace at China’s FDA

By Rebecca Robbins

The READOUT
The Readout

A conspicuous absence of pharma execs & a bad April Fools’ Day joke

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Moderna’s pitch deck & biotech’s hottest stock

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

That big Incyte trial & cancer-fighting mercenaries

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

The hangover from the last biotech boom & what will become of Incyte?

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A Bluebird muddle & your take on a big migraine trial

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Alexion can’t get any respect & your call on a big biotech catalyst

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Theranos’ mystery man revealed & Arena’s ongoing comeback

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A bad week for Bob Hugin & a worse two months for a new IPO

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Pharma’s biggest ad spenders & and a potentially crisper CRISPR

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Biopharma’s M&A malaise & an index for Chinese biotech

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Biotech’s awkward SXSW & Bob Hugin’s political education

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A parade of patents & conference calls for dummies

By Damian Garde and Meghana Keshavan

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.